Marfan Sartan: a randomized, double-blind, placebo-controlled trial.
暂无分享,去创建一个
F. Tubach | G. Jondeau | L. Faivre | C. Boileau | P. Aegerter | D. Attias | J. Wolf | G. Habib | S. Odent | S. Dupuis-Girod | Y. Dulac | G. Delorme | J. Ropers | D. Détaint | F. Arnoult | F. Sassolas | A. Basquin | H. Plauchu | Julie Thomas-Chabaneix | O. Milleron | M. Barthelet | T. Edouard | P. Collignon | S. Naudion | N. Pangaud | Sophie Naudion
[1] S. Colan,et al. Atenolol versus losartan in children and young adults with Marfan's syndrome. , 2014, The New England journal of medicine.
[2] H. Connolly,et al. Of Marfan's syndrome, mice, and medications. , 2014, The New England journal of medicine.
[3] Deepak L. Bhatt,et al. Refining calcium test for diagnosis of medullary thyroid cancer: cutoffs, procedures and safety , 2014, The New England journal of medicine.
[4] F. Hu,et al. Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. , 2013, Mayo Clinic proceedings.
[5] A. Hughes,et al. Meta‐analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index , 2013, British journal of clinical pharmacology.
[6] H. Krum,et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. , 2012, Circulation.
[7] C. Ki,et al. A comparison of the ghent and revised ghent nosologies for the diagnosis of marfan syndrome in an adult korean population , 2012, American journal of medical genetics. Part A.
[8] E. Arbustini,et al. The new Ghent criteria for Marfan syndrome: what do they change? , 2012, Clinical genetics.
[9] F. Tubach,et al. Aortic Event Rate in the Marfan Population: A Cohort Study , 2012, Circulation.
[10] H. Dietz,et al. Pravastatin Reduces Marfan Aortic Dilation , 2011, Circulation.
[11] D. Judge,et al. Angiotensin II Type 2 Receptor Signaling Attenuates Aortic Aneurysm in Mice Through ERK Antagonism , 2011, Science.
[12] Helmut Baumgartner,et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). , 2010, European heart journal.
[13] P. Robinson,et al. Congenital heart disease Cardiovascular manifestations in men and women carrying a FBN 1 mutation , 2010 .
[14] C. van Breemen,et al. Effectiveness of combination of losartan potassium and doxycycline versus single-drug treatments in the secondary prevention of thoracic aortic aneurysm in Marfan syndrome. , 2010, The Journal of thoracic and cardiovascular surgery.
[15] Laurence Faivre,et al. The revised Ghent nosology for the Marfan syndrome , 2010, Journal of Medical Genetics.
[16] F. Tubach,et al. Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome. , 2010, Archives of cardiovascular diseases.
[17] A. John Camm,et al. The Esc Textbook of Cardiovascular Medicine , 2009 .
[18] C. van Breemen,et al. Long‐term effects of losartan on structure and function of the thoracic aorta in a mouse model of Marfan syndrome , 2009, British journal of pharmacology.
[19] E. O’Brien. Renal sympathetic denervation for resistant hypertension , 2009, The Lancet.
[20] G. Jondeau,et al. Identification of the minimal combination of clinical features in probands for efficient mutation detection in the FBN1 gene , 2009, European Journal of Human Genetics.
[21] W. Nichols,et al. Effects of Arterial Stiffness, Pulse Wave Velocity, and Wave Reflections on the Central Aortic Pressure Waveform , 2008, Journal of clinical hypertension.
[22] G. Jondeau,et al. Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome. , 2007, The American journal of cardiology.
[23] P Segers,et al. Aortic reflection coefficients and their association with global indexes of wave reflection in healthy controls and patients with Marfan's syndrome. , 2006, American journal of physiology. Heart and circulatory physiology.
[24] Marc K. Halushka,et al. Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome , 2006, Science.
[25] William Stewart,et al. Recommendations for chamber quantification. , 2006, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.
[26] Richard B Devereux,et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[27] P. Engelfriet,et al. Aortic root growth in men and women with the Marfan's syndrome. , 2005, The American journal of cardiology.
[28] P. Boutouyrie,et al. Central pulse pressure is a major determinant of ascending aorta dilation in Marfan syndrome. , 1999, Circulation.
[29] A de Roos,et al. Changes in aortic distensibility and pulse wave velocity assessed with magnetic resonance imaging following beta-blocker therapy in the Marfan syndrome. , 1998, The American journal of cardiology.
[30] R E Pyeritz,et al. Revised diagnostic criteria for the Marfan syndrome. , 1996, American journal of medical genetics.
[31] J. Duranteau,et al. Effects of the angiotensin type I receptor antagonist, losartan, on systemic and regional vascular responses to lower body negative pressure in healthy volunteers. , 1995, British journal of clinical pharmacology.
[32] E. Murphy,et al. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. , 1994, The New England journal of medicine.
[33] R. Devereux,et al. Two-dimensional echocardiographic aortic root dimensions in normal children and adults. , 1989, The American journal of cardiology.
[34] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[35] V. Aboyans,et al. [2014 ESC Guidelines on the diagnosis and treatment of aortic diseases]. , 2014, Kardiologia polska.
[36] J. Stockman,et al. Angiotensin II Blockade and Aortic-Root Dilation in Marfan's Syndrome , 2010 .
[37] A. Evangelista,et al. Diseases of the aorta and trauma to the aorta and heart , 2022 .